abstract: @entity4297 are classified into two broad categories: acyanotic and @entity75 . The most common @entity75 are @entity1757 , @entity118 , @entity473 , @entity849 , @entity2461 , @entity472 and @entity1498 . @entity712 is the primary concern in @entity1 with @entity75 . The most common @entity75 are tetralogy of @entity3886 . In @entity1 with @entity75 , @entity519 is more of a problem than @entity712 . Suspicion of a @entity4297 should be raised by the presence of feeding difficulties in association with @entity7405 , sweating and @entity74 , or severe @entity851 . Follow-up of @entity1 with @entity299 should follow the schedule of routine care for healthy babies with some modifications, such as administration of influenza and pneumococcal vaccines. More frequent follow-up is required if @entity712 is present. Family psychosocial issues should also be addressed. One of the main roles for the family physician is to help the parents put the diagnosis in perspective by clarifying expectations and misconceptions, and answering specific questions.

title: Caring for XXXX with @entity299 and their families.

answer: @entity1 :: (9606,Species) :: ['infants']


abstract: The incidence of @entity263 ( @entity263 ) among middle-aged @entity1 has increased rapidly. For many of these @entity1 , curatively intended treatment does more harm than good. Established prognostic factors are @entity5 stage and grade. As a result of earlier detection a majority of @entity1 now have nonpalpable @entity5 (T1c) of intermediate grade (Gleason score 6). @entity1486 in serum in such cases is generally at a low level and not a reliable predictor of prognosis. Altogether there is an urgent need for adjunctive prognostic indicators. In the search for relevant @entity5 markers for improved @entity1 selection an exploration of the proteome (the @entity1 proteins) could be fruitful. This paper critically reviews the use of 2-dimensional gel electrophoresis (2-DE) for proteome research. Additional steps such as image analysis and mass spectrometry are described. Techniques based on non-2-DE platforms: surface-enhanced laser desorption/ionization (SELDI), isotope coded affinity tags (ICAT) and array-based technologies are also summarized. Although labor-intensive and time-consuming, 2-DE is presently the most powerful method for analysis of cellular protein phenotype and may potentially reveal gene regulations that cannot be detected on a genetic level.

title: Proteomics in XXXX research.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'patient', 'men']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['early prostate cancer', 'PCa']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity1486 :: ('354', 'Gene') :: ['Prostate specific antigen']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']


abstract: @entity66 represents a physical and molecular barrier to axonal regeneration and has become an important target for regeneration research in chronic @entity1566 . Although many methods have been proven useful for the prevention of scar formation in an @entity131 model, to date no effective method has been described to remove an existing @entity66 in a @entity8638 . The chronic lesion possesses an irregular shaped scar that lines the entire perimeter of the cavity. In the present study, we used rose bengal, a molecule commonly used for biological staining, injected into the cavity at the injury site of Long-Evans @entity35 spinal cord (5 weeks after 25-mm contusion injury). Visible light was used to illuminate the injury site. Histological observation illustrates that at least partial @entity66 is ablated by rose bengal/illumination. The lack of @entity40 ( @entity40 ) immunoreactivity at the @entity66 coupled with the reduction of @entity40 density surrounding spared tissue suggests that this photochemical scar ablation preferentially kills astrocytes at the scar tissue but also reacts, to a lesser degree, in the spared tissue. There is an observed reduction of Basso, Beattie, and Bresnahan (BBB) scale scores after scar ablation, but it is not statistically significant from stabilized behavioral scoring prior to the scar ablation treatment. Our findings indicate that the rose bengal/illumination is feasible for ablation of the @entity66 which surrounds an irregular lesion cavity in shape. The scar ablation might provide a permissive environment for the regenerating axons when enriched by cellular or drug therapy.

title: Photochemical scar ablation in chronically contused spinal cord of XXXX .

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['acute injury']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Glial scar', 'glial scar tissue', 'glial scar']

entities_list: @entity40 :: ('24387(Tax:10116)', 'Gene') :: ['GFAP', 'glial fibrillary acidic protein']

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury']

entities_list: @entity8638 :: ('MESH:D020208', 'Disease') :: ['chronic injury']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: The main purpose of this report is to describe nine cases of @entity2173 with @entity267 in the absence of history of corneal @entity1066 or @entity1036 . The authors studied nine @entity1 with @entity2173 . Each @entity1 underwent complete ophthalmologic and dermatologic examinations. Three @entity1 underwent excision of @entity957 of the conjunctiva. There were five male and four female @entity1 , with a mean age of 14 years and a range of 5 to 21 years. Seven had @entity957 . All @entity1 had spontaneous diffuse corneal stromal scars without clinical evidence of @entity1036 and no previous history of corneal @entity1066 . The corneal sensation was intact. None of the @entity1 had @entity1066 of the @entity267 . One @entity1 had @entity936 . The clinical and histopathologic changes of the @entity267 and conjunctiva in @entity1 with @entity2173 appear to be similar to the changes occurring in sun-exposed skin. This suggests that direct exposure of corneal and conjunctival tissue to ultraviolet light in @entity1 with @entity2173 is the primary cause of @entity2318 in the @entity267 and conjunctiva, which leads to @entity1018 .

title: Spontaneous corneal @entity2318 in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1018 :: ('MESH:D054062', 'Disease') :: ['loss of vision']

entities_list: @entity267 :: ('MESH:D065306', 'Disease') :: ['cornea', 'primary spontaneous corneal scarring']

entities_list: @entity1036 :: ('MESH:D007634', 'Disease') :: ['keratitis', 'infectious keratitis']

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer', 'ulceration', 'ulcers']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['conjunctival squamous cell carcinoma', 'squamous cell carcinoma']

entities_list: @entity2173 :: ('MESH:D014983', 'Disease') :: ['xeroderma pigmentosum']

entities_list: @entity936 :: ('MESH:D015352', 'Disease') :: ['dry eye syndrome']

answer: @entity2173 :: (MESH:D014983,Disease) :: ['xeroderma pigmentosum']


abstract: The main purpose of this report is to describe nine cases of @entity2173 with @entity267 in the absence of history of corneal @entity1066 or @entity1036 . The authors studied nine @entity1 with @entity2173 . Each @entity1 underwent complete ophthalmologic and dermatologic examinations. Three @entity1 underwent excision of @entity957 of the conjunctiva. There were five male and four female @entity1 , with a mean age of 14 years and a range of 5 to 21 years. Seven had @entity957 . All @entity1 had spontaneous diffuse corneal stromal scars without clinical evidence of @entity1036 and no previous history of corneal @entity1066 . The corneal sensation was intact. None of the @entity1 had @entity1066 of the @entity267 . One @entity1 had @entity936 . The clinical and histopathologic changes of the @entity267 and conjunctiva in @entity1 with @entity2173 appear to be similar to the changes occurring in sun-exposed skin. This suggests that direct exposure of corneal and conjunctival tissue to ultraviolet light in @entity1 with @entity2173 is the primary cause of @entity2318 in the @entity267 and conjunctiva, which leads to @entity1018 .

title: Spontaneous corneal XXXX in @entity2173 .

answer: @entity2318 :: (MESH:D002921,Disease) :: ['scarring']


abstract: This paper presents the case report of a 67-year-old @entity1 who came to our hospital suffering from severe @entity3061 of the 11th thoracic vertebral body. The @entity1 has been suffering from @entity1358 for 2 years. During a routine control the above-mentioned lesion was found by chance. A few days later @entity158 started in the thoracolumbar region. Treatment was intended to be palliative. Therefore, we looked for an option to stabilize the vertebral body as minimally invasive as possible. Because of a destroyed trailing edge of the vertebra, "normal" kyphoplasty was not possible. For this reason, we performed a modification, using one filled balloon as a kind of curtain between the vertebral body and spinal canal. With this technique we achieved an optimal filling of the destroyed vertebral body with cement, without any leakage. Two days postoperatively, the @entity1 could leave our hospital without any @entity158 symptoms.

title: [Modified percutaneous balloon kyphoplasty at XXXX of 11th thoracic vertebra and communication with the spinal canal. Case report and review of the literature].

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma']

entities_list: @entity3061 :: ('MESH:D010014', 'Disease') :: ['osteolysis']

answer: @entity3061 :: (MESH:D010014,Disease) :: ['osteolysis']


abstract: Fifty @entity1 (37 females and 13 males) with first febrile urinary tract infections were studied to assess the value of @entity29582 ( @entity9409 ) scan in detecting inflammatory changes of @entity2885 ( @entity2885 ). These findings were compared with renal ultrasonography (US). We also evaluated the reliability of clinical and laboratory observations in diagnosing @entity2885 ( @entity2885 ). All @entity1 had micturating cystourethrography (MCUG). @entity9409 -documented @entity2885 was present in 29 (58%) @entity1 . Only four @entity1 (8%) demonstrated changes suggestive of @entity2885 on renal ultrasonography. @entity3025 ( @entity3025 ) was documented in 17 (47%) of the total group and in 13 (45%) of those with abnormal @entity9409 scan. Follow-up @entity9409 scan in 15 @entity1 with initial abnormal findings showed complete recovery in seven (47%). Our data have shown that @entity9409 renal scan is the most useful investigational procedure in @entity1 with febrile UTI. The diagnosis of @entity2885 , depending on clinical and laboratory data, is unreliable. Renal US alone can miss serious @entity8 . MCUG remains the most sensitive procedure to detect @entity3025 and it should be performed in all @entity1 with UTI and abbormal @entity9409 scan. Early detection of @entity2885 allows the prompt introduction of antimicrobial agents in those @entity1 and can prevent or decrease @entity8 and its complications.

title: Febrile urinary tract infection in @entity1 : Role of XXXX ( @entity9409 ) scan and other imaging techniques.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity29582 :: ('MESH:D019783', 'Chemical') :: ['99MTc-dimercaptosuccinic acid']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal damage', 'renal defects']

entities_list: @entity3025 :: ('MESH:D014718', 'Disease') :: ['VUR', 'Vesicoureteric reflux']

entities_list: @entity2885 :: ('MESH:D011704', 'Disease') :: ['APN', 'acute pyelonephritis']

answer: @entity29582 :: (MESH:D019783,Chemical) :: ['99MTc-dimercaptosuccinic acid']


abstract: Fifty @entity1 (37 females and 13 males) with first febrile urinary tract infections were studied to assess the value of @entity29582 ( @entity9409 ) scan in detecting inflammatory changes of @entity2885 ( @entity2885 ). These findings were compared with renal ultrasonography (US). We also evaluated the reliability of clinical and laboratory observations in diagnosing @entity2885 ( @entity2885 ). All @entity1 had micturating cystourethrography (MCUG). @entity9409 -documented @entity2885 was present in 29 (58%) @entity1 . Only four @entity1 (8%) demonstrated changes suggestive of @entity2885 on renal ultrasonography. @entity3025 ( @entity3025 ) was documented in 17 (47%) of the total group and in 13 (45%) of those with abnormal @entity9409 scan. Follow-up @entity9409 scan in 15 @entity1 with initial abnormal findings showed complete recovery in seven (47%). Our data have shown that @entity9409 renal scan is the most useful investigational procedure in @entity1 with febrile UTI. The diagnosis of @entity2885 , depending on clinical and laboratory data, is unreliable. Renal US alone can miss serious @entity8 . MCUG remains the most sensitive procedure to detect @entity3025 and it should be performed in all @entity1 with UTI and abbormal @entity9409 scan. Early detection of @entity2885 allows the prompt introduction of antimicrobial agents in those @entity1 and can prevent or decrease @entity8 and its complications.

title: Febrile urinary tract infection in @entity1 : Role of @entity29582 ( XXXX ) scan and other imaging techniques.

answer: @entity9409 :: (MESH:D004113,Chemical) :: ['DMSA']


abstract: Fifty @entity1 (37 females and 13 males) with first febrile urinary tract infections were studied to assess the value of @entity29582 ( @entity9409 ) scan in detecting inflammatory changes of @entity2885 ( @entity2885 ). These findings were compared with renal ultrasonography (US). We also evaluated the reliability of clinical and laboratory observations in diagnosing @entity2885 ( @entity2885 ). All @entity1 had micturating cystourethrography (MCUG). @entity9409 -documented @entity2885 was present in 29 (58%) @entity1 . Only four @entity1 (8%) demonstrated changes suggestive of @entity2885 on renal ultrasonography. @entity3025 ( @entity3025 ) was documented in 17 (47%) of the total group and in 13 (45%) of those with abnormal @entity9409 scan. Follow-up @entity9409 scan in 15 @entity1 with initial abnormal findings showed complete recovery in seven (47%). Our data have shown that @entity9409 renal scan is the most useful investigational procedure in @entity1 with febrile UTI. The diagnosis of @entity2885 , depending on clinical and laboratory data, is unreliable. Renal US alone can miss serious @entity8 . MCUG remains the most sensitive procedure to detect @entity3025 and it should be performed in all @entity1 with UTI and abbormal @entity9409 scan. Early detection of @entity2885 allows the prompt introduction of antimicrobial agents in those @entity1 and can prevent or decrease @entity8 and its complications.

title: Febrile urinary tract infection in XXXX : Role of @entity29582 ( @entity9409 ) scan and other imaging techniques.

answer: @entity1 :: (9606,Species) :: ['children']


abstract: BACKGROUND: Activated macrophages play an important role in the pathogenesis of @entity63 . It has been postulated that detection of heat released by activated inflammatory cells of @entity731 may predict @entity397 and @entity715 . Previous ex vivo studies have shown that there is thermal heterogeneity in @entity1 carotid @entity731 . METHODS AND RESULTS: To measure the temperature of @entity1 arteries in vivo, we developed a catheter-based technique. Ninety @entity1 (45 with normal coronary arteries, 15 with @entity5749 [ @entity5749 ], 15 with @entity1459 [ @entity1459 ], and 15 with @entity583 [ @entity583 ]) were studied. The thermistor of the thermography catheter has a temperature accuracy of 0.05 degrees C, a time constant of 300 ms, and a spatial resolution of 0.5 mm. Temperature was constant within the arteries of the control subjects, whereas most @entity731 showed higher temperature compared with healthy vessel wall. Temperature differences between @entity731 and healthy vessel wall increased progressively from @entity5749 to @entity583 @entity1 (difference of plaque temperature from background temperature, 0. 106+/-0.110 degrees C in @entity5749 , 0.683+/-0.347 degrees C in @entity1459 , and 1. 472+/-0.691 degrees C in @entity583 ). Heterogeneity within the plaque was shown in 20%, 40%, and 67% of the @entity1 with @entity5749 , @entity1459 , and @entity583 , respectively, whereas no heterogeneity was shown in the control subjects. CONCLUSIONS: Thermal heterogeneity within @entity1 @entity731 coronary arteries was shown in vivo by use of a special thermography catheter. This heterogeneity is larger in @entity1459 and @entity583 , suggesting that it may be related to the pathogenesis.

title: Thermal heterogeneity within @entity1 XXXX coronary arteries detected in vivo: A new method of detection by application of a special thermography catheter.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'acute myocardial infarction']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['acute ischemic syndromes']

entities_list: @entity5749 :: ('MESH:D060050', 'Disease') :: ['stable angina', 'SA']

entities_list: @entity1459 :: ('MESH:D000789', 'Disease') :: ['UA', 'unstable angina']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['plaque rupture']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic', 'atherosclerotic plaque', 'atherosclerotic plaques']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

answer: @entity731 :: (MESH:D050197,Disease) :: ['atherosclerotic']


abstract: BACKGROUND: Activated macrophages play an important role in the pathogenesis of @entity63 . It has been postulated that detection of heat released by activated inflammatory cells of @entity731 may predict @entity397 and @entity715 . Previous ex vivo studies have shown that there is thermal heterogeneity in @entity1 carotid @entity731 . METHODS AND RESULTS: To measure the temperature of @entity1 arteries in vivo, we developed a catheter-based technique. Ninety @entity1 (45 with normal coronary arteries, 15 with @entity5749 [ @entity5749 ], 15 with @entity1459 [ @entity1459 ], and 15 with @entity583 [ @entity583 ]) were studied. The thermistor of the thermography catheter has a temperature accuracy of 0.05 degrees C, a time constant of 300 ms, and a spatial resolution of 0.5 mm. Temperature was constant within the arteries of the control subjects, whereas most @entity731 showed higher temperature compared with healthy vessel wall. Temperature differences between @entity731 and healthy vessel wall increased progressively from @entity5749 to @entity583 @entity1 (difference of plaque temperature from background temperature, 0. 106+/-0.110 degrees C in @entity5749 , 0.683+/-0.347 degrees C in @entity1459 , and 1. 472+/-0.691 degrees C in @entity583 ). Heterogeneity within the plaque was shown in 20%, 40%, and 67% of the @entity1 with @entity5749 , @entity1459 , and @entity583 , respectively, whereas no heterogeneity was shown in the control subjects. CONCLUSIONS: Thermal heterogeneity within @entity1 @entity731 coronary arteries was shown in vivo by use of a special thermography catheter. This heterogeneity is larger in @entity1459 and @entity583 , suggesting that it may be related to the pathogenesis.

title: Thermal heterogeneity within XXXX @entity731 coronary arteries detected in vivo: A new method of detection by application of a special thermography catheter.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: We report the results of the release and tape-shortening techniques in @entity7502 pubovaginal slings. Of female @entity1 who had undergone mid-urethral sling procedures [ @entity2701 -free vaginal tape procedure and suburethral @entity7502 ( @entity9618 )], in cases in which postoperative retention occurred, the @entity1 were offered release or tape cutting. @entity1 reporting postoperative @entity322 underwent a tape-shortening procedure. In these @entity1 , the tape was shortened by the use of clips. Mean follow-up time after the release and/or the shortening operations was 9.9 months (range 6-18). A total of 15 @entity1 , ranging from 41 to 75 years old (mean 58.3) were included in this study. Upon the latest follow-up, six @entity1 exhibited prolonged urinary retention and subsequently underwent a release procedure (n=5) or a tape-cutting procedure (n=1). After the release procedure, all @entity1 remained continent, but one @entity1 's urinary retention issues were not resolved, and she subsequently underwent a tape-cutting. Both of the @entity1 who underwent the cutting procedure then developed recurrent stress @entity322 . The tape-shortening technique was conducted with nine @entity1 . Seven of these @entity1 recovered their continence, and no one @entity1 experienced any urinary retention or other voiding difficulties. Two @entity1 reported only minimal stress leakage and elected to undergo no further interventions. Our findings suggest that @entity2701 plays a substantial role in @entity2701 -free mid-urethral sling procedures.

title: Significance of XXXX in @entity2701 -free mid-urethral sling procedures: a preliminary study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women', 'patient']

entities_list: @entity322 :: ('MESH:D014549', 'Disease') :: ['urinary incontinence']

entities_list: @entity7502 :: ('MESH:D011126', 'Chemical') :: ['polypropylene']

answer: @entity2701 :: (MESH:D018781,Disease) :: ['tension']


abstract: We report the results of the release and tape-shortening techniques in @entity7502 pubovaginal slings. Of female @entity1 who had undergone mid-urethral sling procedures [ @entity2701 -free vaginal tape procedure and suburethral @entity7502 ( @entity9618 )], in cases in which postoperative retention occurred, the @entity1 were offered release or tape cutting. @entity1 reporting postoperative @entity322 underwent a tape-shortening procedure. In these @entity1 , the tape was shortened by the use of clips. Mean follow-up time after the release and/or the shortening operations was 9.9 months (range 6-18). A total of 15 @entity1 , ranging from 41 to 75 years old (mean 58.3) were included in this study. Upon the latest follow-up, six @entity1 exhibited prolonged urinary retention and subsequently underwent a release procedure (n=5) or a tape-cutting procedure (n=1). After the release procedure, all @entity1 remained continent, but one @entity1 's urinary retention issues were not resolved, and she subsequently underwent a tape-cutting. Both of the @entity1 who underwent the cutting procedure then developed recurrent stress @entity322 . The tape-shortening technique was conducted with nine @entity1 . Seven of these @entity1 recovered their continence, and no one @entity1 experienced any urinary retention or other voiding difficulties. Two @entity1 reported only minimal stress leakage and elected to undergo no further interventions. Our findings suggest that @entity2701 plays a substantial role in @entity2701 -free mid-urethral sling procedures.

title: Significance of @entity2701 in XXXX -free mid-urethral sling procedures: a preliminary study.

answer: @entity2701 :: (MESH:D018781,Disease) :: ['tension']


abstract: BACKGROUND: It is postulated that @entity455 formation and remodeling involves a balance between vascular cell death and cell proliferation. @entity2533 ( @entity2533 ) is a pleiotropic factor expressed within vascular cells that regulates cell growth in a tissue-specific manner. This study tested the hypothesis that the control of vascular cell apoptosis involves cell type-specific regulation by @entity2533 . METHODS AND RESULTS: In response to serum withdrawal, cultured endothelial cells and vascular smooth muscle cells exhibited apoptosis as evidenced by DNA laddering and quantitated by analysis of nuclear chromatin morphology. Addition of @entity2533 to endothelial cells in serum-free media further potentiated the induction of apoptosis in a dose-dependent fashion. Moreover, @entity2533 promoted endothelial cell death despite the presence of 10% serum. However, endothelial cells plated on collagen I were resistant to @entity2533 -induced apoptosis. This antiapoptotic influence of the matrix was mimicked by integrin activation with anti- @entity8652 antibodies and associated with increased expression of the antiapoptotic factor @entity588 . In accord with the hypothesis that the modulation of antiapoptotic gene expression may mediate the effects of @entity2533 and @entity8652 integrins on cell fate, we observed that endothelial cells with constitutive upregulation of @entity588 remained viable despite exposure to @entity2533 in serum-free conditions. In contrast to the proapoptotic effect of @entity2533 in endothelial cells, addition of @entity2533 to vascular smooth muscle cells in serum-free media inhibited apoptosis. CONCLUSIONS: These findings suggest that the effect of cytokines such as @entity2533 on cell fate is contextual and is modulated by cell-matrix interactions in a cell type-specific manner.

title: Vascular cell apoptosis: cell type-specific modulation by transforming growth factor- XXXX in endothelial cells versus smooth muscle cells.

entities_list: @entity2533 :: ('7040', 'Gene') :: ['Transforming growth factor-beta1', 'TGF-beta1']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular lesion']

answer: @entity8652 :: (3779,Gene) :: ['beta1']


abstract: BACKGROUND: Surgery alone is the appropriate first-line treatment for @entity1 with @entity12878 ( @entity12878 ). Nevertheless, there are reports of local recurrences and @entity3 , especially in the cellular subtype. The authors evaluated the outcome of @entity1 with @entity12878 who were enrolled in either the International Society of Pediatric Oncology (SIOP) 93-01/GPOH or the SIOP 2001/GPOH @entity3969 Study and Trial. METHODS: In total, 50 @entity1 with @entity12878 were analyzed. Eleven @entity1 were suspected antenatally of having a @entity703 . The median age at diagnosis was 18.5 days. Central pathologic review was performed for all specimens. The median observation time was 4.2 years. RESULTS: Forty-five @entity1 underwent initial surgery. Five @entity1 older than 6 months received preoperative chemotherapy. Twenty-nine @entity5 were classic @entity12878 , and 21 @entity5 were cellular @entity12878 . Nine @entity1 had a Stage III @entity12878 , 5 of those @entity1 had @entity5 ruptures, and 8 had positive surgical margins. After they underwent nephrectomy, 40 @entity1 received no further treatment. For the entire group, event-free survival (EFS) (94%) and overall survival (OS) (95%) were excellent. @entity1 with a cellular @entity12878 , @entity1 with age 3 @entity16557 , and @entity1 with Stage III @entity12878 had lower EFS. Three @entity1 developed recurrent disease, and 2 of those @entity1 died. @entity3 to the brain, lung, and liver were observed in 1 @entity1 . CONCLUSIONS: Radical nephrectomy with accurate surgical-pathologic staging is the standard of care for @entity1 with @entity12878 . Nonetheless, a subgroup of @entity1 with @entity12878 (Stage III cellular @entity12878 in @entity1 age 3 @entity16557 ) tends to develop recurrences more often. Further prospective studies will be needed to verify this finding and should help determine whether these @entity1 may benefit from adjuvant therapy.

title: XXXX --a report from the Gesellschaft fur P  diatrische Onkologie und H  matologie (GPOH).

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity12878 :: ('MESH:D018201', 'Disease') :: ['MN', 'mesoblastic nephroma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'Metastases']

entities_list: @entity16557 :: ('MESH:C536013', 'Disease') :: ['months or older']

entities_list: @entity3969 :: ('MESH:D009396', 'Disease') :: ['Nephroblastoma']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['renal tumor']

answer: @entity12878 :: (MESH:D018201,Disease) :: ['Mesoblastic nephroma']


abstract: Dysfunctional maturation of neural networks, particularly hippocampus-prefrontal networks, may be of particular interest in determining the pathophysiology of @entity161 . @entity12781 ( @entity212 )-induced symptoms in @entity1 appear to offer a more complete model of @entity161 than do @entity4944 -induced symptoms. This study investigated the effects of intermittent i.p. injections of @entity212 (7.5 mg/kg) on cell proliferation and survival of granule cells in the dentate gyrus of the @entity35 brain using quantitative immunohistochemical techniques for @entity1603 ( @entity1603 )-positive cells. After repeated @entity212 injection for 14 days, mean scores for stereotyped behavior increased with the number of injections, while scores for @entity2055 and backpedaling as serotonergic behaviors gradually decreased. The number of @entity1603 -positive cells decreased by 23% in the subgranular zone of the dentate gyrus by 24 h after repeated injections. However, decreased levels of @entity1603 -positive cells returned to control levels within 1 week. Differentiation of newly formed cells was not influenced. Repeated @entity212 administration after @entity1603 injection did not exert any effects on survival of newly generated cells. These findings suggest that transient disturbances of cell proliferation in the dentate gyrus occur under @entity212 -related @entity146 . Whether disturbed cell proliferation would thus be closely implicated in the development of behavioral sensitization induced by @entity212 administration is unclear, but this would possibly result from adaptation to new pharmacological conditions under behavioral sensitization or stressful conditions of @entity212 -related abnormal behaviors. Further studies are required to elucidate the biological significance of hippocampal neurogenesis in the mechanisms underlying the development of @entity73 and the @entity716 of @entity161 .

title: Effects of repeated XXXX administration on adult hippocampal neurogenesis in the @entity35 .

entities_list: @entity1603 :: ('MESH:D001973', 'Chemical') :: ['BrdU', "5-bromo-2'-deoxyuridine"]

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['behavioral abnormalities']

entities_list: @entity12781 :: ('MESH:D010622', 'Chemical') :: ['Phencyclidine']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive dysfunctions']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

entities_list: @entity716 :: ('MESH:D011605', 'Disease') :: ['psychosis']

entities_list: @entity4944 :: ('MESH:D000661', 'Chemical') :: ['amphetamine']

answer: @entity12781 :: (MESH:D010622,Chemical) :: ['phencyclidine']


abstract: Dysfunctional maturation of neural networks, particularly hippocampus-prefrontal networks, may be of particular interest in determining the pathophysiology of @entity161 . @entity12781 ( @entity212 )-induced symptoms in @entity1 appear to offer a more complete model of @entity161 than do @entity4944 -induced symptoms. This study investigated the effects of intermittent i.p. injections of @entity212 (7.5 mg/kg) on cell proliferation and survival of granule cells in the dentate gyrus of the @entity35 brain using quantitative immunohistochemical techniques for @entity1603 ( @entity1603 )-positive cells. After repeated @entity212 injection for 14 days, mean scores for stereotyped behavior increased with the number of injections, while scores for @entity2055 and backpedaling as serotonergic behaviors gradually decreased. The number of @entity1603 -positive cells decreased by 23% in the subgranular zone of the dentate gyrus by 24 h after repeated injections. However, decreased levels of @entity1603 -positive cells returned to control levels within 1 week. Differentiation of newly formed cells was not influenced. Repeated @entity212 administration after @entity1603 injection did not exert any effects on survival of newly generated cells. These findings suggest that transient disturbances of cell proliferation in the dentate gyrus occur under @entity212 -related @entity146 . Whether disturbed cell proliferation would thus be closely implicated in the development of behavioral sensitization induced by @entity212 administration is unclear, but this would possibly result from adaptation to new pharmacological conditions under behavioral sensitization or stressful conditions of @entity212 -related abnormal behaviors. Further studies are required to elucidate the biological significance of hippocampal neurogenesis in the mechanisms underlying the development of @entity73 and the @entity716 of @entity161 .

title: Effects of repeated @entity12781 administration on adult hippocampal neurogenesis in the XXXX .

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: BACKGROUND: Induction chemotherapy before surgical resection increases survival compared with surgical resection alone in @entity1 with stage IIIA-N2 @entity1149 ( @entity1149 ). We hypothesized that, following a response to induction chemotherapy, surgical resection would be superior to thoracic radiotherapy as locoregional therapy. METHODS: Selected @entity1 with histologic or cytologic proven stage IIIA-N2 @entity1149 were given three cycles of @entity902 -based induction chemotherapy. Responding @entity1 were subsequently randomly assigned to surgical resection or radiotherapy. Survival curves were estimated using Kaplan-Meier analyses from time of randomization. RESULTS: Induction chemotherapy resulted in a response rate of 61% (95% confidence interval [CI] = 57% to 65%) among the 579 eligible @entity1 . A total of 167 @entity1 were allocated to resection and 165 to radiotherapy. Of the 154 (92%) @entity1 who underwent surgery, 14% had an exploratory thoracotomy, 50% a radical resection, 42% a pathologic downstaging, and 5% a pathologic complete response; 4% died after surgery. Postoperative radiotherapy was administered to 62 (40%) of @entity1 in the surgery arm. Among the 154 (93%) irradiated @entity1 , overall compliance to the radiotherapy prescription was 55%, and grade 3/4 acute and late esophageal and pulmonary toxic effects occurred in 4% and 7%; one @entity1 died of radiation @entity55 . Median and 5-year overall survival for @entity1 randomly assigned to resection versus radiotherapy were 16.4 versus 17.5 months and 15.7% versus 14%, respectively (hazard ratio = 1.06, 95% CI = 0.84 to 1.35). Rates of progression-free survival were also similar in both groups. CONCLUSION: In selected @entity1 with pathologically proven stage IIIA-N2 @entity1149 and a response to induction chemotherapy, surgical resection did not improve overall or progression-free survival compared with radiotherapy. In view of its low morbidity and mortality, radiotherapy should be considered the preferred locoregional treatment for these @entity1 .

title: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small-cell lung cancer']


abstract: BACKGROUND AND AIM: To estimate if a meaningful relationship exists between body mass index (BMI) and the entity of @entity453 , coronary events and mortality in a cohort of consecutive @entity1 with suspected @entity453 ( @entity453 ). METHODS AND RESULTS: In this prospective study, we enrolled 1299 consecutive @entity1 (905 [69.7%] males) who had undergone coronary angiography. Our sample consisted of 477 @entity1 (36.8%) of normal weight; 567 (43.6%) overweight and 255 (19.6%) @entity28 , according to the WHO classification. Conventional cardiovascular risk factors, BMI, endothelial function and subclinical @entity32 were studied. Different angiographic @entity453 scores were used to quantify @entity453 . In overweight and @entity28 @entity1 , respect to normal weight population, there is a higher prevalence of @entity101 , @entity1007 and @entity6 , but BMI was not significantly associated with greater extent of @entity453 . At follow-up (mean: 40; range: 24-82 months) @entity28 and overweight @entity1 showed a higher incidence of coronary events compared to the normal weight population (74.9% [ @entity28 ] versus 62.7% [overweight] versus 53.2% [normal weight]; adjusted relative risk [ @entity28 versus overweight]: 1.08 [95% confidence interval: 1.02-1.23]; P<0.05; and adjusted RR [ @entity28 versus normal weight]: 1.17 [95% CI: 1.10-1.42], P<0.01). Mortality from @entity299 was not significant within the categories. The Cox regression model showed flow mediated dilation (P<0.0001), high-sensitive @entity1851 (P=0.022) and BMI (P=0.045) as independent predictors of acute coronary events. CONCLUSION: BMI is not associated with the extent of @entity453 and mortality. The higher incidence of coronary events in @entity28 subjects is only partly explained by conventional associated risk factors. Impaired endothelial function and sub-clinical @entity32 could be involved in this association but BMI itself is related to cardiovascular events suggesting that other unknown (or not considered) pathways are involved.

title: Influence of body mass index on extent of XXXX and @entity299 in a cohort of @entity1 at risk of @entity453 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity1007 :: ('MESH:D006937', 'Disease') :: ['hypercholesterolemia']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary atherosclerotic burden', 'coronary artery disease', 'coronary atherosclerosis']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C reactive protein']

answer: @entity453 :: (MESH:D003324,Disease) :: ['coronary atherosclerosis']


abstract: BACKGROUND AND AIM: To estimate if a meaningful relationship exists between body mass index (BMI) and the entity of @entity453 , coronary events and mortality in a cohort of consecutive @entity1 with suspected @entity453 ( @entity453 ). METHODS AND RESULTS: In this prospective study, we enrolled 1299 consecutive @entity1 (905 [69.7%] males) who had undergone coronary angiography. Our sample consisted of 477 @entity1 (36.8%) of normal weight; 567 (43.6%) overweight and 255 (19.6%) @entity28 , according to the WHO classification. Conventional cardiovascular risk factors, BMI, endothelial function and subclinical @entity32 were studied. Different angiographic @entity453 scores were used to quantify @entity453 . In overweight and @entity28 @entity1 , respect to normal weight population, there is a higher prevalence of @entity101 , @entity1007 and @entity6 , but BMI was not significantly associated with greater extent of @entity453 . At follow-up (mean: 40; range: 24-82 months) @entity28 and overweight @entity1 showed a higher incidence of coronary events compared to the normal weight population (74.9% [ @entity28 ] versus 62.7% [overweight] versus 53.2% [normal weight]; adjusted relative risk [ @entity28 versus overweight]: 1.08 [95% confidence interval: 1.02-1.23]; P<0.05; and adjusted RR [ @entity28 versus normal weight]: 1.17 [95% CI: 1.10-1.42], P<0.01). Mortality from @entity299 was not significant within the categories. The Cox regression model showed flow mediated dilation (P<0.0001), high-sensitive @entity1851 (P=0.022) and BMI (P=0.045) as independent predictors of acute coronary events. CONCLUSION: BMI is not associated with the extent of @entity453 and mortality. The higher incidence of coronary events in @entity28 subjects is only partly explained by conventional associated risk factors. Impaired endothelial function and sub-clinical @entity32 could be involved in this association but BMI itself is related to cardiovascular events suggesting that other unknown (or not considered) pathways are involved.

title: Influence of body mass index on extent of @entity453 and @entity299 in a cohort of @entity1 at risk of XXXX .

answer: @entity453 :: (MESH:D003324,Disease) :: ['coronary artery disease']


abstract: BACKGROUND AND AIM: To estimate if a meaningful relationship exists between body mass index (BMI) and the entity of @entity453 , coronary events and mortality in a cohort of consecutive @entity1 with suspected @entity453 ( @entity453 ). METHODS AND RESULTS: In this prospective study, we enrolled 1299 consecutive @entity1 (905 [69.7%] males) who had undergone coronary angiography. Our sample consisted of 477 @entity1 (36.8%) of normal weight; 567 (43.6%) overweight and 255 (19.6%) @entity28 , according to the WHO classification. Conventional cardiovascular risk factors, BMI, endothelial function and subclinical @entity32 were studied. Different angiographic @entity453 scores were used to quantify @entity453 . In overweight and @entity28 @entity1 , respect to normal weight population, there is a higher prevalence of @entity101 , @entity1007 and @entity6 , but BMI was not significantly associated with greater extent of @entity453 . At follow-up (mean: 40; range: 24-82 months) @entity28 and overweight @entity1 showed a higher incidence of coronary events compared to the normal weight population (74.9% [ @entity28 ] versus 62.7% [overweight] versus 53.2% [normal weight]; adjusted relative risk [ @entity28 versus overweight]: 1.08 [95% confidence interval: 1.02-1.23]; P<0.05; and adjusted RR [ @entity28 versus normal weight]: 1.17 [95% CI: 1.10-1.42], P<0.01). Mortality from @entity299 was not significant within the categories. The Cox regression model showed flow mediated dilation (P<0.0001), high-sensitive @entity1851 (P=0.022) and BMI (P=0.045) as independent predictors of acute coronary events. CONCLUSION: BMI is not associated with the extent of @entity453 and mortality. The higher incidence of coronary events in @entity28 subjects is only partly explained by conventional associated risk factors. Impaired endothelial function and sub-clinical @entity32 could be involved in this association but BMI itself is related to cardiovascular events suggesting that other unknown (or not considered) pathways are involved.

title: Influence of body mass index on extent of @entity453 and XXXX in a cohort of @entity1 at risk of @entity453 .

answer: @entity299 :: (MESH:D006331,Disease) :: ['cardiac events']


abstract: BACKGROUND AND AIM: To estimate if a meaningful relationship exists between body mass index (BMI) and the entity of @entity453 , coronary events and mortality in a cohort of consecutive @entity1 with suspected @entity453 ( @entity453 ). METHODS AND RESULTS: In this prospective study, we enrolled 1299 consecutive @entity1 (905 [69.7%] males) who had undergone coronary angiography. Our sample consisted of 477 @entity1 (36.8%) of normal weight; 567 (43.6%) overweight and 255 (19.6%) @entity28 , according to the WHO classification. Conventional cardiovascular risk factors, BMI, endothelial function and subclinical @entity32 were studied. Different angiographic @entity453 scores were used to quantify @entity453 . In overweight and @entity28 @entity1 , respect to normal weight population, there is a higher prevalence of @entity101 , @entity1007 and @entity6 , but BMI was not significantly associated with greater extent of @entity453 . At follow-up (mean: 40; range: 24-82 months) @entity28 and overweight @entity1 showed a higher incidence of coronary events compared to the normal weight population (74.9% [ @entity28 ] versus 62.7% [overweight] versus 53.2% [normal weight]; adjusted relative risk [ @entity28 versus overweight]: 1.08 [95% confidence interval: 1.02-1.23]; P<0.05; and adjusted RR [ @entity28 versus normal weight]: 1.17 [95% CI: 1.10-1.42], P<0.01). Mortality from @entity299 was not significant within the categories. The Cox regression model showed flow mediated dilation (P<0.0001), high-sensitive @entity1851 (P=0.022) and BMI (P=0.045) as independent predictors of acute coronary events. CONCLUSION: BMI is not associated with the extent of @entity453 and mortality. The higher incidence of coronary events in @entity28 subjects is only partly explained by conventional associated risk factors. Impaired endothelial function and sub-clinical @entity32 could be involved in this association but BMI itself is related to cardiovascular events suggesting that other unknown (or not considered) pathways are involved.

title: Influence of body mass index on extent of @entity453 and @entity299 in a cohort of XXXX at risk of @entity453 .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The role of magnetic resonance imaging (MRI) in @entity263 evaluation is controversial and likely underestimated. Technological advances over the past 5  years have demonstrated that multiparametric MRI, including diffusion-weighted imaging (DWI) and dynamic contrast-enhanced MRI, can evaluate the @entity5 burden of a newly diagnosed @entity263 more accurately than sextant biopsy protocols. @entity5 risk, defined by the D'Amico criteria, hence can be re-evaluated by multiparametric MRI. As a result, there is increasing evidence that MRI before repeat or even initial biopsy can accurately select @entity1 who require immediate biopsies and those in whom biopsy could be deferred. Also, a relationship between apparent diffusion coefficient (ADC), calculated from DWI, and Gleason score was found. Thus, MRI before biopsy helps to detect high-grade @entity5 to target biopsies within areas of low ADC values. To achieve good targeting accuracy, transrectal ultrasound (TRUS)-MRI image registration is necessary. Three-dimensional deformable registration is sufficiently accurate to match TRUS and MRI volumes with a topographic precision of 1  mm. Real-time MRI-guided biopsy is another technique under evaluation. Both approaches will allow for increasing acceptance of focal therapies, should these techniques be validated in the future.

title: Value of multiparametric MRI in the work-up of XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumor', 'actual tumor', 'tumors']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']


abstract: AIM: To compare walking function, @entity158 , and @entity1295 in adults with @entity306 ( @entity306 ) 7 years after an initial survey. METHOD: A multidimensional questionnaire was mailed to 226 @entity1 with unilateral (hemiplegic) or bilateral (diplegic) @entity306 who had participated in a 1999 survey. @entity1 with additional diagnoses were excluded. Special emphasis was placed on @entity1 with deterioration in walking. The questionnaire was the same as in 1999. RESULTS: One hundred and forty-nine @entity1 (76 males, 73 females; mean age 40y 5mo, SD 10y 7mo, range 24-76y) with a diagnosis of unilateral (n=81) or bilateral (n=68) @entity306 responded. Fifty-two per cent of all @entity1 reported deterioration in walking function since debut of walking, compared with 39% 7 years previously. In @entity1 with bilateral @entity306 , 71% reported deteriorated walking, compared with 37% of @entity1 with unilateral @entity306 . @entity1 with deteriorated walking function had greater @entity158 frequency, @entity158 intensity, impact of @entity158 on daily activities, and physical @entity1295 and reduced balance. The number of @entity1 reporting overall mobility problems was almost double compared with 7 years previously. INTERPRETATION: The main finding was an increased prevalence of deteriorated walking, significantly associated with bilateral @entity306 , @entity158 , @entity1295 , and reduced balance. Rehabilitation programmes addressing these areas are needed.

title: Walking function, @entity158 , and XXXX in adults with @entity306 : a 7-year follow-up study.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Participants', 'people', 'People']

entities_list: @entity306 :: ('MESH:D002547', 'Disease') :: ['cerebral palsy', 'spastic CP', 'CP']

answer: @entity1295 :: (MESH:D005221,Disease) :: ['fatigue']


abstract: AIM: To compare walking function, @entity158 , and @entity1295 in adults with @entity306 ( @entity306 ) 7 years after an initial survey. METHOD: A multidimensional questionnaire was mailed to 226 @entity1 with unilateral (hemiplegic) or bilateral (diplegic) @entity306 who had participated in a 1999 survey. @entity1 with additional diagnoses were excluded. Special emphasis was placed on @entity1 with deterioration in walking. The questionnaire was the same as in 1999. RESULTS: One hundred and forty-nine @entity1 (76 males, 73 females; mean age 40y 5mo, SD 10y 7mo, range 24-76y) with a diagnosis of unilateral (n=81) or bilateral (n=68) @entity306 responded. Fifty-two per cent of all @entity1 reported deterioration in walking function since debut of walking, compared with 39% 7 years previously. In @entity1 with bilateral @entity306 , 71% reported deteriorated walking, compared with 37% of @entity1 with unilateral @entity306 . @entity1 with deteriorated walking function had greater @entity158 frequency, @entity158 intensity, impact of @entity158 on daily activities, and physical @entity1295 and reduced balance. The number of @entity1 reporting overall mobility problems was almost double compared with 7 years previously. INTERPRETATION: The main finding was an increased prevalence of deteriorated walking, significantly associated with bilateral @entity306 , @entity158 , @entity1295 , and reduced balance. Rehabilitation programmes addressing these areas are needed.

title: Walking function, XXXX , and @entity1295 in adults with @entity306 : a 7-year follow-up study.

answer: @entity158 :: (MESH:D010146,Disease) :: ['pain']


abstract: AIM: To compare walking function, @entity158 , and @entity1295 in adults with @entity306 ( @entity306 ) 7 years after an initial survey. METHOD: A multidimensional questionnaire was mailed to 226 @entity1 with unilateral (hemiplegic) or bilateral (diplegic) @entity306 who had participated in a 1999 survey. @entity1 with additional diagnoses were excluded. Special emphasis was placed on @entity1 with deterioration in walking. The questionnaire was the same as in 1999. RESULTS: One hundred and forty-nine @entity1 (76 males, 73 females; mean age 40y 5mo, SD 10y 7mo, range 24-76y) with a diagnosis of unilateral (n=81) or bilateral (n=68) @entity306 responded. Fifty-two per cent of all @entity1 reported deterioration in walking function since debut of walking, compared with 39% 7 years previously. In @entity1 with bilateral @entity306 , 71% reported deteriorated walking, compared with 37% of @entity1 with unilateral @entity306 . @entity1 with deteriorated walking function had greater @entity158 frequency, @entity158 intensity, impact of @entity158 on daily activities, and physical @entity1295 and reduced balance. The number of @entity1 reporting overall mobility problems was almost double compared with 7 years previously. INTERPRETATION: The main finding was an increased prevalence of deteriorated walking, significantly associated with bilateral @entity306 , @entity158 , @entity1295 , and reduced balance. Rehabilitation programmes addressing these areas are needed.

title: Walking function, @entity158 , and @entity1295 in adults with XXXX : a 7-year follow-up study.

answer: @entity306 :: (MESH:D002547,Disease) :: ['cerebral palsy']


abstract: BACKGROUND: It has been thought that @entity2975 (PA) injections do not have inflammatory side effects. Recent evidence shows that local and regional delayed adverse effects may appear with its use. OBJECTIVE: To evaluate the clinical complaints and follow-up of @entity1 with delayed immune-mediated adverse effects related to PA injections. METHODS: Prospective, case-series study of 10 @entity1 with delayed adverse effects related to PA injections. Only @entity1 with intermediate or delayed adverse effects related to @entity2975 injection were included. @entity1 with immediate side effects were excluded. @entity1 underwent clinical management, follow-up, and when possible, blood tests and biopsy. RESULTS: Average latency period to onset of symptoms was 10 months (range 2-36). Tender, inflammatory nodules--granulomas--with pseudo-abscesses were commonly seen. @entity854 were found in all analyzed cases. After 20.1 months average follow-up, five @entity1 were in remission, two had recurrent bouts, and three were lost to follow-up, one of them in remission. CONCLUSION: Although it happens infrequently, local and regional delayed and recurrent granulomatous reactions may complicate PA gel injections.

title: Delayed immune-mediated adverse effects related to XXXX dermal fillers: clinical findings, management, and follow-up.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['Laboratory abnormalities']

entities_list: @entity2975 :: ('CHEBI:51135', 'Chemical') :: ['polyacrylamide']

answer: @entity2975 :: (CHEBI:51135,Chemical) :: ['polyacrylamide']


abstract: BACKGROUND: Individuals with electrocardiographically determined left @entity123 (ECG LVH) are at risk of multiple @entity65 ( @entity65 ) outcomes simultaneously. The study sought to characterise the competing incidences for subtypes of first @entity65 events or non- @entity65 death in those with and without ECG LVH. METHODS: @entity1 in the @entity731 Risk in Communities (ARIC) Study were included. ECG LVH was defined according to Sokolow-Lyon criteria. Competing Cox models were used to compare hazards for diverse outcomes within groups (e.g., among those with ECG LVH) and for a given event between groups (ECG LVH vs. no ECG LVH). RESULTS: After 15 years, @entity1 with ECG LVH at baseline (N=383) had a cumulative incidence of first @entity65 events and non- @entity65 deaths of 29.2% and 6.1%, respectively (HR 4.86; 95% CI 3.04 to 7.77). In @entity1 without ECG LVH (N=6576) the incidence of any first @entity65 event and non- @entity65 death was 18.9% and 6.9%, respectively (HR 2.67; 2.39 to 2.98). Similar associations were observed in @entity1 (N=381 with and N=8187 without ECG LVH). @entity301 ( @entity301 ) was the most common first event in @entity1 with ECG LVH (15.0%) and @entity712 was the most common first event in @entity1 with ECG LVH (10.5%). After adjustment for risk factors including systolic blood pressure, any @entity65 event remained the most likely first event. CONCLUSIONS: Among middle-aged individuals with ECG LVH, the most likely first events are @entity301 in @entity1 and @entity712 in @entity1 ; these results may have implications for preventive approaches.

title: Competing cardiovascular outcomes associated with electrocardiographic left XXXX : the @entity731 Risk in Communities Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Participants', 'men']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['CHD', 'Coronary heart disease']

entities_list: @entity123 :: ('MESH:D024741', 'Disease') :: ['ventricular hypertrophy']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['Atherosclerosis']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['CVD', 'cardiovascular disease']

answer: @entity123 :: (MESH:D024741,Disease) :: ['ventricular hypertrophy']


abstract: BACKGROUND: Individuals with electrocardiographically determined left @entity123 (ECG LVH) are at risk of multiple @entity65 ( @entity65 ) outcomes simultaneously. The study sought to characterise the competing incidences for subtypes of first @entity65 events or non- @entity65 death in those with and without ECG LVH. METHODS: @entity1 in the @entity731 Risk in Communities (ARIC) Study were included. ECG LVH was defined according to Sokolow-Lyon criteria. Competing Cox models were used to compare hazards for diverse outcomes within groups (e.g., among those with ECG LVH) and for a given event between groups (ECG LVH vs. no ECG LVH). RESULTS: After 15 years, @entity1 with ECG LVH at baseline (N=383) had a cumulative incidence of first @entity65 events and non- @entity65 deaths of 29.2% and 6.1%, respectively (HR 4.86; 95% CI 3.04 to 7.77). In @entity1 without ECG LVH (N=6576) the incidence of any first @entity65 event and non- @entity65 death was 18.9% and 6.9%, respectively (HR 2.67; 2.39 to 2.98). Similar associations were observed in @entity1 (N=381 with and N=8187 without ECG LVH). @entity301 ( @entity301 ) was the most common first event in @entity1 with ECG LVH (15.0%) and @entity712 was the most common first event in @entity1 with ECG LVH (10.5%). After adjustment for risk factors including systolic blood pressure, any @entity65 event remained the most likely first event. CONCLUSIONS: Among middle-aged individuals with ECG LVH, the most likely first events are @entity301 in @entity1 and @entity712 in @entity1 ; these results may have implications for preventive approaches.

title: Competing cardiovascular outcomes associated with electrocardiographic left @entity123 : the XXXX Risk in Communities Study.

answer: @entity731 :: (MESH:D050197,Disease) :: ['Atherosclerosis']


abstract: PURPOSE: To investigate the expression of @entity12020 ( @entity12020 ) in the retina of @entity1 subjects with @entity6 , and @entity12020 , CD105, and gelatinase B in proliferative @entity6 (PVR) epiretinal membranes. METHODS: Twelve donor eyes from six subjects with @entity6 , 10 eyes from five nondiabetic subjects, 14 PDR membranes, and five PVR membranes were studied by immunohistochemical techniques. In situ zymography was used to examine gelatinolytic activity in four PDR membranes. RESULTS: In nondiabetic retinas, there was no immunoreactivity for @entity12020 . @entity6 showed immunoreactivity for @entity12020 in ganglion cells and microglia. Vascular endothelial cells in PDR membranes expressed @entity12020 , CD105, and gelatinase B in 10 (71.4%), 11 (78.6%), and 5 (35.7%) membranes, respectively. Myofibroblasts in PDR membranes expressed @entity12020 , and gelatinase B in 14 (100%), and 6 (42.9%) membranes, respectively. There was a significant correlation between the number of blood vessels expressing the panendothelial marker @entity2280 and the number of blood vessels expressing @entity12020 (r = 0.7884; P = 0.0008), and CD105 (r = 0.6901; P = 0.0063), and the number of myofibroblasts expressing @entity12020 (r = 0.5922; P = 0.0257). There was a significant correlation between the number of myofibroblasts expressing alpha-smooth muscle actin and the number of myofibroblasts expressing @entity12020 (r = 0.8393; P = 0.0002). In situ zymography showed the presence of gelatinolytic activity in vascular endothelial cells in PDR membranes. Myofibroblasts in PVR membranes expressed @entity12020 , and gelatinase B. CONCLUSIONS: These results suggest a possible role of @entity12020 , CD105, and gelatinase B in the pathogenesis of proliferative @entity989 .

title: Expression of angiogenic and fibrogenic factors in proliferative XXXX .

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetic retinas', 'diabetic retinopathy (PDR) and proliferative vitreoretinopathy', 'diabetes mellitus']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['vitreoretinal disorders']

entities_list: @entity12020 :: ('1490', 'Gene') :: ['connective tissue growth factor', 'CTGF']

answer: @entity989 :: (MESH:D012164,Disease) :: ['vitreoretinal disorders']


abstract: BACKGROUND: American Heart Association/American @entity64 Association guidelines recommend initiating treatment with IV @entity1456 (tPA) in acute @entity385 @entity1 without suspected @entity1003 prior to availability of clotting results; however, little or no data support this practice. We sought to identify how often @entity4461 were responsible for withholding IV tPA at our institution. METHODS: We conducted a retrospective review of our prospectively acquired Get With the Guidelines @entity64 database from January 2003 to April 2008. All @entity1 underwent clinical evaluation by a neurologist, diagnostic neuroimaging, and laboratory testing on admission. We classified @entity1 with absolute contraindications to IV tPA as ineligible, and those with warnings/relative contraindications or potentially treatable factors as potentially eligible. RESULTS: Of 2,335 considered for analysis, 470 (20.1%) @entity1 presented to our emergency department (ED) within 3 hours. Among these, 147 (31.3%) received IV tPA in our ED, 102 (21.7%) had an absolute contraindication, and 221 (47%) had a reason to consider withholding tPA. Only 30/470 (6.4%) of potential thrombolysis @entity1 were discovered to have international normalized ratio > or =1.7 or platelets < or =100,000/microL, and of these, 28 were suspected a priori due to known @entity1003 from medication or illness. Only 2/470 (0.4%) @entity1 had an unsuspected @entity1003 that ultimately prevented thrombolysis. CONCLUSIONS: Based on the experience of a large thrombolysis referral center, @entity64 @entity1 without suspected clotting abnormality can safely begin thrombolytic therapy before clotting results are available. These data support the current practice guidelines, and may reassure clinicians that the benefits of early administration greatly outweigh the risks due to an unsuspected @entity548 diathesis.

title: XXXX rarely prevents IV thrombolysis in acute @entity385 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'Stroke']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity1456 :: ('100128998', 'Gene') :: ['tissue plasminogen activator']

entities_list: @entity1003 :: ('MESH:D001778', 'Disease') :: ['coagulopathy']

entities_list: @entity4461 :: ('MESH:D020141', 'Disease') :: ['blood clotting abnormalities']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity1003 :: (MESH:D001778,Disease) :: ['Unsuspected coagulopathy']


abstract: BACKGROUND: American Heart Association/American @entity64 Association guidelines recommend initiating treatment with IV @entity1456 (tPA) in acute @entity385 @entity1 without suspected @entity1003 prior to availability of clotting results; however, little or no data support this practice. We sought to identify how often @entity4461 were responsible for withholding IV tPA at our institution. METHODS: We conducted a retrospective review of our prospectively acquired Get With the Guidelines @entity64 database from January 2003 to April 2008. All @entity1 underwent clinical evaluation by a neurologist, diagnostic neuroimaging, and laboratory testing on admission. We classified @entity1 with absolute contraindications to IV tPA as ineligible, and those with warnings/relative contraindications or potentially treatable factors as potentially eligible. RESULTS: Of 2,335 considered for analysis, 470 (20.1%) @entity1 presented to our emergency department (ED) within 3 hours. Among these, 147 (31.3%) received IV tPA in our ED, 102 (21.7%) had an absolute contraindication, and 221 (47%) had a reason to consider withholding tPA. Only 30/470 (6.4%) of potential thrombolysis @entity1 were discovered to have international normalized ratio > or =1.7 or platelets < or =100,000/microL, and of these, 28 were suspected a priori due to known @entity1003 from medication or illness. Only 2/470 (0.4%) @entity1 had an unsuspected @entity1003 that ultimately prevented thrombolysis. CONCLUSIONS: Based on the experience of a large thrombolysis referral center, @entity64 @entity1 without suspected clotting abnormality can safely begin thrombolytic therapy before clotting results are available. These data support the current practice guidelines, and may reassure clinicians that the benefits of early administration greatly outweigh the risks due to an unsuspected @entity548 diathesis.

title: @entity1003 rarely prevents IV thrombolysis in acute XXXX .

answer: @entity385 :: (MESH:D002544,Disease) :: ['ischemic stroke']


abstract: PURPOSE: Since the combination of @entity416 and @entity2600 has successfully been used as a first-line treatment in @entity14 ( @entity14 ), we expected promising results when given as a second-line treatment to metastatic colorectal @entity1 who had been pretreated with @entity1487 and @entity901 . METHODS: Thirty-three @entity14 @entity1 participated in this study and received an oral dose of 1,000 mg/m(2 ) @entity416 twice daily on days 1-14 and a dose of 100 mg/m(2) @entity2600 infused over 90 min on days 1 and 8, every 3 weeks. RESULTS: The overall response rate in intent-to-treat was 33.3% (95% CI, 21.5-58.3%), including one complete response (3.0%) and ten partial responses (30.3%); 12 @entity1 (36.4%) had disease stabilization and only 9 (27.3%) progressed. The median time to progression was 6.7 months (95% CI, 4.8-8.6 months). After a median follow-up time of 12 months, nine @entity1 (27.3%) were still alive with metastatic disease. The median response duration for all @entity1 was 6.7 months (95% CI, 3.9-9.5 months) and the median overall survival was 13.4 months (95% CI, 11.0-15.8 months) with a 1-year survival rate of 55.4%. Myelosuppression was commonly observed; NCI-CTC (v 2.0) grade 3/4 @entity1398 , however, occurred in eight (24%) @entity1 and grade 3 @entity417 was seen in one @entity1 (3%). The most common (grade 3/4) non-hematological @entity137 was @entity294 (15%) and the other severe grade 3/4 @entity137 included @entity1209 in one @entity1 (3%), @entity3136 in one @entity1 (3%), @entity8566 in one @entity1 (3%). CONCLUSIONS: The combination of @entity416 and @entity2600 is an effective and well-tolerated regimen for second-line treatment of @entity14 . However, further phase III trials are required to clarify its use in the treatment of metastastic @entity14 @entity1 who have been pretreated with @entity1487 and @entity901 .

title: The combination of @entity416 and @entity2600 in treating @entity1487 - and XXXX -pretreated @entity14 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin', 'Oxaliplatin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan']

entities_list: @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine']

entities_list: @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity8566 :: ('MESH:D060831', 'Disease') :: ['hand-foot syndrome']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer', 'metastatic colorectal cancer', 'MCRC']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-Fluorouracil', '5-fluorouracil']

entities_list: @entity1209 :: ('MESH:D020250', 'Disease') :: ['nausea/vomiting']

answer: @entity901 :: (MESH:C030110,Chemical) :: ['Oxaliplatin']


abstract: PURPOSE: Since the combination of @entity416 and @entity2600 has successfully been used as a first-line treatment in @entity14 ( @entity14 ), we expected promising results when given as a second-line treatment to metastatic colorectal @entity1 who had been pretreated with @entity1487 and @entity901 . METHODS: Thirty-three @entity14 @entity1 participated in this study and received an oral dose of 1,000 mg/m(2 ) @entity416 twice daily on days 1-14 and a dose of 100 mg/m(2) @entity2600 infused over 90 min on days 1 and 8, every 3 weeks. RESULTS: The overall response rate in intent-to-treat was 33.3% (95% CI, 21.5-58.3%), including one complete response (3.0%) and ten partial responses (30.3%); 12 @entity1 (36.4%) had disease stabilization and only 9 (27.3%) progressed. The median time to progression was 6.7 months (95% CI, 4.8-8.6 months). After a median follow-up time of 12 months, nine @entity1 (27.3%) were still alive with metastatic disease. The median response duration for all @entity1 was 6.7 months (95% CI, 3.9-9.5 months) and the median overall survival was 13.4 months (95% CI, 11.0-15.8 months) with a 1-year survival rate of 55.4%. Myelosuppression was commonly observed; NCI-CTC (v 2.0) grade 3/4 @entity1398 , however, occurred in eight (24%) @entity1 and grade 3 @entity417 was seen in one @entity1 (3%). The most common (grade 3/4) non-hematological @entity137 was @entity294 (15%) and the other severe grade 3/4 @entity137 included @entity1209 in one @entity1 (3%), @entity3136 in one @entity1 (3%), @entity8566 in one @entity1 (3%). CONCLUSIONS: The combination of @entity416 and @entity2600 is an effective and well-tolerated regimen for second-line treatment of @entity14 . However, further phase III trials are required to clarify its use in the treatment of metastastic @entity14 @entity1 who have been pretreated with @entity1487 and @entity901 .

title: The combination of @entity416 and XXXX in treating @entity1487 - and @entity901 -pretreated @entity14 .

answer: @entity2600 :: (MESH:C051890,Chemical) :: ['irinotecan']


abstract: PURPOSE: Since the combination of @entity416 and @entity2600 has successfully been used as a first-line treatment in @entity14 ( @entity14 ), we expected promising results when given as a second-line treatment to metastatic colorectal @entity1 who had been pretreated with @entity1487 and @entity901 . METHODS: Thirty-three @entity14 @entity1 participated in this study and received an oral dose of 1,000 mg/m(2 ) @entity416 twice daily on days 1-14 and a dose of 100 mg/m(2) @entity2600 infused over 90 min on days 1 and 8, every 3 weeks. RESULTS: The overall response rate in intent-to-treat was 33.3% (95% CI, 21.5-58.3%), including one complete response (3.0%) and ten partial responses (30.3%); 12 @entity1 (36.4%) had disease stabilization and only 9 (27.3%) progressed. The median time to progression was 6.7 months (95% CI, 4.8-8.6 months). After a median follow-up time of 12 months, nine @entity1 (27.3%) were still alive with metastatic disease. The median response duration for all @entity1 was 6.7 months (95% CI, 3.9-9.5 months) and the median overall survival was 13.4 months (95% CI, 11.0-15.8 months) with a 1-year survival rate of 55.4%. Myelosuppression was commonly observed; NCI-CTC (v 2.0) grade 3/4 @entity1398 , however, occurred in eight (24%) @entity1 and grade 3 @entity417 was seen in one @entity1 (3%). The most common (grade 3/4) non-hematological @entity137 was @entity294 (15%) and the other severe grade 3/4 @entity137 included @entity1209 in one @entity1 (3%), @entity3136 in one @entity1 (3%), @entity8566 in one @entity1 (3%). CONCLUSIONS: The combination of @entity416 and @entity2600 is an effective and well-tolerated regimen for second-line treatment of @entity14 . However, further phase III trials are required to clarify its use in the treatment of metastastic @entity14 @entity1 who have been pretreated with @entity1487 and @entity901 .

title: The combination of @entity416 and @entity2600 in treating XXXX - and @entity901 -pretreated @entity14 .

answer: @entity1487 :: (MESH:D005472,Chemical) :: ['5-Fluorouracil']


abstract: PURPOSE: Since the combination of @entity416 and @entity2600 has successfully been used as a first-line treatment in @entity14 ( @entity14 ), we expected promising results when given as a second-line treatment to metastatic colorectal @entity1 who had been pretreated with @entity1487 and @entity901 . METHODS: Thirty-three @entity14 @entity1 participated in this study and received an oral dose of 1,000 mg/m(2 ) @entity416 twice daily on days 1-14 and a dose of 100 mg/m(2) @entity2600 infused over 90 min on days 1 and 8, every 3 weeks. RESULTS: The overall response rate in intent-to-treat was 33.3% (95% CI, 21.5-58.3%), including one complete response (3.0%) and ten partial responses (30.3%); 12 @entity1 (36.4%) had disease stabilization and only 9 (27.3%) progressed. The median time to progression was 6.7 months (95% CI, 4.8-8.6 months). After a median follow-up time of 12 months, nine @entity1 (27.3%) were still alive with metastatic disease. The median response duration for all @entity1 was 6.7 months (95% CI, 3.9-9.5 months) and the median overall survival was 13.4 months (95% CI, 11.0-15.8 months) with a 1-year survival rate of 55.4%. Myelosuppression was commonly observed; NCI-CTC (v 2.0) grade 3/4 @entity1398 , however, occurred in eight (24%) @entity1 and grade 3 @entity417 was seen in one @entity1 (3%). The most common (grade 3/4) non-hematological @entity137 was @entity294 (15%) and the other severe grade 3/4 @entity137 included @entity1209 in one @entity1 (3%), @entity3136 in one @entity1 (3%), @entity8566 in one @entity1 (3%). CONCLUSIONS: The combination of @entity416 and @entity2600 is an effective and well-tolerated regimen for second-line treatment of @entity14 . However, further phase III trials are required to clarify its use in the treatment of metastastic @entity14 @entity1 who have been pretreated with @entity1487 and @entity901 .

title: The combination of XXXX and @entity2600 in treating @entity1487 - and @entity901 -pretreated @entity14 .

answer: @entity416 :: (MESH:C110904,Chemical) :: ['capecitabine']


abstract: PURPOSE: Since the combination of @entity416 and @entity2600 has successfully been used as a first-line treatment in @entity14 ( @entity14 ), we expected promising results when given as a second-line treatment to metastatic colorectal @entity1 who had been pretreated with @entity1487 and @entity901 . METHODS: Thirty-three @entity14 @entity1 participated in this study and received an oral dose of 1,000 mg/m(2 ) @entity416 twice daily on days 1-14 and a dose of 100 mg/m(2) @entity2600 infused over 90 min on days 1 and 8, every 3 weeks. RESULTS: The overall response rate in intent-to-treat was 33.3% (95% CI, 21.5-58.3%), including one complete response (3.0%) and ten partial responses (30.3%); 12 @entity1 (36.4%) had disease stabilization and only 9 (27.3%) progressed. The median time to progression was 6.7 months (95% CI, 4.8-8.6 months). After a median follow-up time of 12 months, nine @entity1 (27.3%) were still alive with metastatic disease. The median response duration for all @entity1 was 6.7 months (95% CI, 3.9-9.5 months) and the median overall survival was 13.4 months (95% CI, 11.0-15.8 months) with a 1-year survival rate of 55.4%. Myelosuppression was commonly observed; NCI-CTC (v 2.0) grade 3/4 @entity1398 , however, occurred in eight (24%) @entity1 and grade 3 @entity417 was seen in one @entity1 (3%). The most common (grade 3/4) non-hematological @entity137 was @entity294 (15%) and the other severe grade 3/4 @entity137 included @entity1209 in one @entity1 (3%), @entity3136 in one @entity1 (3%), @entity8566 in one @entity1 (3%). CONCLUSIONS: The combination of @entity416 and @entity2600 is an effective and well-tolerated regimen for second-line treatment of @entity14 . However, further phase III trials are required to clarify its use in the treatment of metastastic @entity14 @entity1 who have been pretreated with @entity1487 and @entity901 .

title: The combination of @entity416 and @entity2600 in treating @entity1487 - and @entity901 -pretreated XXXX .

answer: @entity14 :: (MESH:D015179,Disease) :: ['metastatic colorectal cancer']


abstract: The local effectiveness and clinical usefulness of multipolar radiofrequency (RF) ablation of @entity96 was evaluated. Sixty-eight image-guided RF sessions were performed using a multipolar device with bipolar electrodes in 53 @entity1 . There were 45 @entity157 ( @entity157 ) and 42 @entity3 with a diameter < or =3 cm (n = 55), 3.1-5 cm (n = 29) and >5 cm (n = 3); 26 nodules were within 5 mm from large vessels. Local effectiveness and complications were evaluated after RF procedures. Mean follow-up was 17 +/- 10 months. Recurrence and survival rates were analysed by the Kaplan-Meier method. The primary and secondary technical effectiveness rate was 82% and 95%, respectively. The major and minor complication rate was 2.9%, respectively. The local @entity5 progression at 1- and 2-years was 5% and 9% for @entity157 nodules and 17% and 31% for @entity3 , respectively; four of 26 nodules (15%) close to vessels showed local progression. The survival at 1 year and 2 years was 97% and 90% for @entity157 and 84% and 68% for @entity3 , respectively. Multipolar RF technique creates ablation zones of adequate size and tailored shape and is effective to treat most @entity96 , including those close to major hepatic vessels.

title: Image-guided multipolar radiofrequency ablation of XXXX : initial clinical results.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['liver tumours']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinomas']

answer: @entity96 :: (MESH:D008113,Disease) :: ['liver tumours']


abstract: @entity3457 ( @entity3457 ) kinases, a closely related family of protein kinases, are involved in cell cycle regulation and differentiation in @entity375 and @entity1 cells. They have not been documented in ciliates. We used PCR to amplify DNA sequences of a ciliated protozoan-- @entity18258 --using primers corresponding to @entity535 sequences that are common to @entity3457 kinases. We isolated and sequenced one putative @entity3457 kinase-like @entity563 / @entity1889 kinase cDNA from @entity18258 . This cDNA, called pcstk1 ( @entity18258 @entity563 / @entity1889 Kinase 1) shared approximately 35% @entity535 identity with @entity3457 kinases from @entity375 . @entity3457 kinases are activated by phosphorylation of specific @entity1889 and @entity669 residues. These two @entity535 residues are conserved in the PCSTK1 sequence at positions Thr 159 and Tyr 161. The PSTAIRE motif, which is characteristic of the CDK2 gene family, cannot be found in ORF of PCSTK1. The highest homology score was to @entity1 @entity8026 , which contains @entity3457 type kinase domains. Comparisons of expression level have shown that pcstk1 is expressed equally in cells at different stages (sexual and asexual). We discussed the possibility, as in other organisms, that a family of @entity3457 kinase genes exists in @entity18258 .

title: Isolation and characterization of a XXXX cDNA clone encoding a putative @entity563 / @entity1889 protein kinase.

entities_list: @entity563 :: ('CHEBI:17822', 'Chemical') :: ['Serine', 'serine']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity18258 :: ('5885', 'Species') :: ['Paramecium caudatum', 'P. caudatum']

entities_list: @entity1889 :: ('CHEBI:26986', 'Chemical') :: ['Threonine', 'threonine']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

entities_list: @entity3457 :: ('OMIM:612348', 'Disease') :: ['Mitogen-activated protein', 'MAP']

answer: @entity18258 :: (5885,Species) :: ['Paramecium']


abstract: @entity3457 ( @entity3457 ) kinases, a closely related family of protein kinases, are involved in cell cycle regulation and differentiation in @entity375 and @entity1 cells. They have not been documented in ciliates. We used PCR to amplify DNA sequences of a ciliated protozoan-- @entity18258 --using primers corresponding to @entity535 sequences that are common to @entity3457 kinases. We isolated and sequenced one putative @entity3457 kinase-like @entity563 / @entity1889 kinase cDNA from @entity18258 . This cDNA, called pcstk1 ( @entity18258 @entity563 / @entity1889 Kinase 1) shared approximately 35% @entity535 identity with @entity3457 kinases from @entity375 . @entity3457 kinases are activated by phosphorylation of specific @entity1889 and @entity669 residues. These two @entity535 residues are conserved in the PCSTK1 sequence at positions Thr 159 and Tyr 161. The PSTAIRE motif, which is characteristic of the CDK2 gene family, cannot be found in ORF of PCSTK1. The highest homology score was to @entity1 @entity8026 , which contains @entity3457 type kinase domains. Comparisons of expression level have shown that pcstk1 is expressed equally in cells at different stages (sexual and asexual). We discussed the possibility, as in other organisms, that a family of @entity3457 kinase genes exists in @entity18258 .

title: Isolation and characterization of a @entity18258 cDNA clone encoding a putative @entity563 / XXXX protein kinase.

answer: @entity1889 :: (CHEBI:26986,Chemical) :: ['threonine']


abstract: @entity3457 ( @entity3457 ) kinases, a closely related family of protein kinases, are involved in cell cycle regulation and differentiation in @entity375 and @entity1 cells. They have not been documented in ciliates. We used PCR to amplify DNA sequences of a ciliated protozoan-- @entity18258 --using primers corresponding to @entity535 sequences that are common to @entity3457 kinases. We isolated and sequenced one putative @entity3457 kinase-like @entity563 / @entity1889 kinase cDNA from @entity18258 . This cDNA, called pcstk1 ( @entity18258 @entity563 / @entity1889 Kinase 1) shared approximately 35% @entity535 identity with @entity3457 kinases from @entity375 . @entity3457 kinases are activated by phosphorylation of specific @entity1889 and @entity669 residues. These two @entity535 residues are conserved in the PCSTK1 sequence at positions Thr 159 and Tyr 161. The PSTAIRE motif, which is characteristic of the CDK2 gene family, cannot be found in ORF of PCSTK1. The highest homology score was to @entity1 @entity8026 , which contains @entity3457 type kinase domains. Comparisons of expression level have shown that pcstk1 is expressed equally in cells at different stages (sexual and asexual). We discussed the possibility, as in other organisms, that a family of @entity3457 kinase genes exists in @entity18258 .

title: Isolation and characterization of a @entity18258 cDNA clone encoding a putative XXXX / @entity1889 protein kinase.

answer: @entity563 :: (CHEBI:17822,Chemical) :: ['serine']


abstract: @entity164 2 @entity6 is a @entity74 , with major consequences for @entity1 , society, and health care services. Good glycemic control is an important aspect of @entity6 management because it has a significant impact on @entity6 -related microvascular and possibly macrovascular complications. Based on our understanding of the pathogenesis of @entity6 , multiple pharmacological interventions have been developed in the past 60 years. Although effective, none have had a lasting effect on glycemic control because of the progressive nature of @entity164 2 @entity6 requiring combination therapies and insulin treatment. In addition, several pharmacologic interventions have undesirable side effects, including @entity4053 and @entity1017 . Drugs targeting the incretin pathway are the latest addition to the available antidiabetes agents. Incretin-based therapy is either delivered orally ( @entity5735 [ @entity5735 ]) inhibitors or injected subcutaneously ( @entity5445 [ @entity5445 ] mimetics and analogues). @entity5735 inhibitors are effective either as a single or combination therapy in lowering glycated hemoglobin, fasting and postprandial @entity413 levels, with a low incidence of @entity4053 and no @entity1017 . There are 3 @entity5735 inhibitors currently available ( @entity12350 , @entity15072 , and @entity12349 ), with more expected to be available in the future. In this article, we review the scientific background for incretin-based therapy and the available evidence regarding the role and efficacy of @entity5735 inhibitors in the treatment of @entity1 with @entity164 2 @entity6 .

title: XXXX inhibitors in clinical practice.

entities_list: @entity5735 :: ('1803', 'Gene') :: ['Dipeptidyl peptidase-4', 'dipeptidyl peptidase-4', 'DPP-4']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity15072 :: ('MESH:C502994', 'Chemical') :: ['saxagliptin']

entities_list: @entity4053 :: ('MESH:D007003', 'Disease') :: ['hypoglycemia']

entities_list: @entity12349 :: ('MESH:C502012', 'Chemical') :: ['vildagliptin']

entities_list: @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain']

entities_list: @entity12350 :: ('MESH:C496398', 'Chemical') :: ['sitagliptin']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['very common worldwide disorder']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity5445 :: ('2641', 'Gene') :: ['glucagon-like peptide-1', 'GLP-1']

answer: @entity5735 :: (1803,Gene) :: ['DPP-4']


abstract: OBJECTIVE: Daily wound assessment, including dressing changes and the removal of old ointments causes discomfort for the @entity1 . We therefore developed a new thermoreversible and transparent gel formulation that allows for filling wounds of different shapes and depths. The aim of the study was to investigate the effect of a wound covering gel on wound healing and the skin's microcirculation. MATERIALS AND METHODS: Investigations were carried out in a standardized and reproducible wound model (hairless @entity19 SKH1/hr, n = 30). Three groups were studied by intravital fluorescence microscopy: treatment with @entity25107 -preserved wound covering gel, a formulation containing 3% @entity4280 ( @entity12468 )- @entity1496 , and physiological saline for control. Microcirculatory standard parameters were analysed. RESULTS: The non-perfused area vanished within 14 days due to angiogenesis. The venular diameter, @entity4 formation and functional capillary density showed no significant differences between the three groups. CONCLUSION: The use of the newly developed wound covering gel has no toxic effects on microcirculation and angiogenesis and reveals no significant differences in the overall assessment of microcirculation compared to the control group and the well-established @entity4279 . The transparent antibacterial wound covering gel allows for direct wound assessment. Due to its thermoreversible gel formulation it enables good wound contact and easy handling.

title: Evaluation of a novel XXXX -preserved wound covering gel on dermal wound healing.

entities_list: @entity25107 :: ('MESH:C012599', 'Chemical') :: ['polihexanide']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['oedema']

entities_list: @entity4280 :: ('MESH:D011205', 'Chemical') :: ['povidone']

entities_list: @entity4279 :: ('MESH:D011206', 'Chemical') :: ['PVP-iodine']

answer: @entity25107 :: (MESH:C012599,Chemical) :: ['polihexanide']


abstract: We report the formation of 830 nm (cw) laser-induced, reversible axonal varicosities, using immunostaining with beta-tubulin, in small and medium diameter, @entity5510 positive, cultured @entity35 DRG neurons. Laser also induced a progressive and statistically significant decrease (p<0.005) in MMP in mitochondria in and between static axonal varicosities. In cell bodies of the neuron, the decrease in MMP was also statistically significant (p<0.05), but the decrease occurred more slowly. Importantly we also report for the first time that 830 nm (cw) laser blocked fast axonal flow, imaged in real time using confocal laser microscopy and JC-1 as mitotracker. Control neurons in parallel cultures remained unaffected with no varicosity formation and no change in MMP. Mitochondrial movement was continuous and measured along the axons at a rate of 0.8 microm/s (range 0.5-2 microm/s), consistent with fast axonal flow. Photoacceptors in the mitochondrial membrane absorb laser and mediate the transduction of laser energy into electrochemical changes, initiating a secondary cascade of intracellular events. In neurons, this results in a decrease in MMP with a concurrent decrease in available @entity855 required for nerve function, including maintenance of microtubules and molecular motors, dyneins and kinesins, responsible for fast axonal flow. Laser-induced neural blockade is a consequence of such changes and provide a mechanism for a neural basis of laser-induced @entity158 relief. The repeated application of laser in a clinical setting modulates nociception and @entity158 . The application of laser therapy for @entity1118 may provide a non-drug alternative for the management of @entity1118 .

title: 830 nm laser irradiation induces varicosity formation, reduces mitochondrial membrane potential and blocks fast axonal flow in small and medium diameter XXXX dorsal root ganglion neurons: implications for the analgesic effects of 830 nm laser.

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['reduces pain', 'pain']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['chronic pain']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: BACKGROUND: @entity2023 ( @entity2023 ) is characterized by @entity32 sustained by dysregulated immune response. T-regulatory cells are involved in @entity2023 pathogenesis, mainly producing @entity688 and transforming growth factor (TGF)-beta. Indeed, there is a functional and allergen-specific defect of T-regulatory cells in @entity2023 . However, there are no data about the influence of allergen exposure on @entity2533 serum levels. Therefore, the aim of this preliminary study was to evaluate @entity2533 serum levels in @entity1 with seasonal @entity2023 . @entity1 were evaluated either outside the pollen season and after 1 preseasonal @entity13366 ( @entity13366 ) course (38 subjects) or during the pollen season (57 subjects). METHODS: All @entity1 were @entity56 to Parietaria and/or grasses alone. @entity2533 was measured by a commercially available kit. Symptoms, drug use and eosinophils were evaluated.Serum allergen-specific IgG and IgA levels were also measured by the ELISA method. RESULTS: @entity2533 serum levels were significantly lower in @entity1 evaluated outside the pollen season in comparison with the other 2 situations. @entity13366 induced the significantly highest @entity2533 serum levels. There was a significant negative relationship between @entity2533 and eosinophils in @entity1 after @entity13366 . IgG and IgA levels were higher in @entity13366 -treated @entity1 . CONCLUSION: This preliminary study provides evidence that @entity2533 serum levels are significantly dependent on allergen exposure.

title: Serum transforming growth factor-beta levels depend on allergen exposure in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity2023 :: ('MESH:D006255', 'Disease') :: ['Allergic rhinitis', 'AR']

entities_list: @entity13366 :: ('MESH:D013362', 'Disease') :: ['sublingual immunotherapy', 'SLIT']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic']

answer: @entity2023 :: (MESH:D006255,Disease) :: ['allergic rhinitis']


abstract: BACKGROUND/AIMS: To describe the clinical outcomes of @entity1 with circumscribed and diffuse @entity3193 treated by proton beam irradiation using a nonsurgical light-field technique. METHODS: A retrospective chart review was performed on a series of 19 @entity1 (19 eyes) with @entity3193 treated with proton beam therapy between July 1988 and August 2005. @entity3193 were treated with proton beam irradiation using a light-field technique and doses ranging from 15 to 30 cobalt Gray equivalents (CGE; CGE = proton Gy x relative biological effectiveness 1.1) in 4 fractions. @entity1 with at least 6 months' follow-up were included in the study. Tumor regression, visual acuity, absorption of subretinal fluid, and treatment-associated complications were evaluated by clinical examination and ultrasonography. RESULTS: Visual acuity improved or remained stable in 14 of 18 eyes (78%). Subretinal fluid was initially present in 16 of 19 eyes (84%), and completely resolved in all 16 eyes. Tumor height, as measured by B-scan ultrasonography, decreased in 18 of 19 eyes and remained stable in 1 of 19, as of the last examination. Complications of radiation developed in 9 of 19 eyes (47%) with the total applied dose ranging from 15 to 30 CGE for these 9 eyes. CONCLUSIONS: Proton beam irradiation using a light-field technique without surgical @entity5 localization is an effective treatment option in managing both circumscribed @entity3193 and @entity2695 associated with @entity3932 . A total proton dose as low as 15 CGE applied in 4 fractions appears to be sufficient to reduce @entity5 size, promote absorption of subretinal fluid, and improve or stabilize vision in most @entity1 .

title: Proton beam irradiation using a light-field technique for the treatment of XXXX .

entities_list: @entity2695 :: ('MESH:D006391', 'Disease') :: ['diffuse hemangiomas']

entities_list: @entity3932 :: ('MESH:D013341', 'Disease') :: ['Sturge-Weber syndrome']

entities_list: @entity3193 :: ('MESH:D015862', 'Disease') :: ['Choroidal hemangiomas', 'choroidal hemangiomas']

answer: @entity3193 :: (MESH:D015862,Disease) :: ['choroidal hemangiomas']


abstract: OBJECTIVE: To study the clinicopathologic features of @entity816 . METHODS: The clinical and pathologic characteristics of 18 cases of @entity816 were retrospectively analyzed. RESULTS: Amongst the 18 cases studied, there was a male predominance (male-to-female ratio = 2:1). The age of @entity1 ranged from 7 to 54 years (mean age = 18.2 years). The @entity5 often occurred in the lateral ventricles (16/18, 88.9%). Most @entity1 presented with @entity10 and @entity391 (11/18, 61.1%), followed by visual disturbance (3/18, 16.7%). Eleven @entity1 (61.1%) had clinical features of @entity2916 , usually in the form of @entity18871 (8/18, 44.4%). Computerized tomography was performed in 10 cases, in which 7 cases were of high density and 5 cases showed contrast enhancement. MRI revealed isointense mass lesion on T1WI (7/11, 63.6%), highly intense lesion on T2WI (10/11, 90.9%) and contrast enhancement in some cases (9/11, 81.8%). Four @entity1 had follow-up information available and all of them were alive from 1 to 5 years (mean = 3.5 years). Histologically, there were bundles of spindle cells mixed with clusters of gemistocytes and @entity4494 -like cells. The spindle cells showed immunoreactivity for glial fibrillary acidic protein (18/18, 100%), while the gemistocytes and @entity4494 -like cells expressed @entity5473 (14/18, 77.8%). Most of the cases (16/18, 88.9%) had @entity1758 index <or= 1%. CONCLUSIONS: @entity816 is a benign @entity1313 with distinctive histopathologic features. The @entity5 typically affects @entity1 and young adults. It is associated with a favorable clinical outcome, especially if completely excised.

title: [Clinicopathologic study of XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumor']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity18871 :: ('MESH:D018322', 'Disease') :: ['facial angiofibroma']

entities_list: @entity2916 :: ('MESH:D014402', 'Disease') :: ['tuberous sclerosis']

entities_list: @entity816 :: ('MESH:D001254', 'Disease') :: ['Subependymal giant cell astrocytoma', 'subependymal giant cell astrocytoma']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

answer: @entity816 :: (MESH:D001254,Disease) :: ['subependymal giant cell astrocytoma']


abstract: PURPOSE: To determine the effects of @entity308 and @entity148 on @entity1 completion of structured cardiac rehabilitation. METHODS: Retrospective chart review of 380 @entity1 with @entity583 , coronary artery bypass graft, @entity951 , or @entity712 referred to cardiac rehabilitation. @entity1 physical capacity was tested by the standard 12-minute @entity4464 ( @entity4464 ). @entity308 , @entity148 , and quality of life were assessed by standard questionnaires. Program completers were contrasted to dropouts on dependent variables at baseline. Baseline and postprogram @entity4464 , @entity308 , @entity148 , and quality of life were also compared in completers by using ANOVA and paired t tests. RESULTS: One-half of entering @entity1 completed the program. Statistically significant differences were observed in baseline @entity308 , @entity148 , and quality of life between program completers and dropouts. Dropouts had higher @entity308 and @entity148 scores and lower quality of life, but there were no differences in @entity4464 . Younger, female @entity1 had higher dropout rates. @entity1 also had higher @entity458 , lower quality of life, and less feet walked than @entity1 . Dropout rate was lowest in @entity1 with coronary artery bypass graft and highest in @entity1 with @entity712 . Both male and female completers evidenced significant improvements in @entity4464 , @entity308 , @entity148 , and quality of life. CONCLUSIONS: Psychological distress makes completion of cardiac rehabilitation difficult. @entity1 need to be assessed early in the intervention so that @entity308 and @entity148 can be identified and managed. Completion of the program is advantageous because it is associated with improvement in all measured variables.

title: Effects of @entity308 and XXXX on adherence to cardiac rehabilitation.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'Women', 'Patient', 'men']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depression']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['chronic heart failure']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['psychological distress']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity148 :: (MESH:D001008,Disease) :: ['anxiety']